Literature DB >> 6261830

Stimuli which provoke secretion of azurophil enzymes from human neutrophils induce increments in adenosine cyclic 3'-5'-monophosphate.

J E Smolen, G Weissmann.   

Abstract

1. Stimuli for human neutrophils were divided into two classes on the basis of their ability to induce degranulation: complete secretagogues provoked release of both azurophil and specific granules, while incomplete secretagogues only induced release of specific granules. 2. Complete secretagogues, which possessed the ability to induce secretion of azurophil granules, also induced transient increments in total cellular cyclic AMP levels: incomplete secretagogues did not. 3. Complete secretagogues, unlike the incomplete variety, also induced further increments of cyclic AMP in prostaglandin E1-pretreated neutrophils. 4. Inhibition of lysosomal enzyme release by prostaglandin E1 was closely correlated with elevated levels of cyclic AMP induced by the prostaglandin alone, than with the much higher transient increment in cyclic AMP produced by stimulation of prostaglandin E1-treated cells. 5. Our results describe the first biochemical difference between neutrophil responses associated with secretion of azurophil granules, as opposed to specific granules: transient increments in cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6261830     DOI: 10.1016/0304-4165(81)90393-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  N-formyl-methionyl-leucyl-phenylalanine (fMLP) inhibits tumour necrosis factor-alpha (TNF-alpha) production on lipopolysaccharide (LPS)-stimulated human neutrophils.

Authors:  M Vulcano; M F Alves Rosa; F S Minnucci; A C Cherñavsky; M A Isturiz
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

2.  Fast deactivation of guinea-pig isolated ileum to C5adesArg: a possible cyclic AMP-dependent mechanism.

Authors:  B Damerau; J Roesler; W Vogt
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

3.  Calmodulin-dependency of human neutrophil phosphodiesterase.

Authors:  T Engerson; J L Legendre; H P Jones
Journal:  Inflammation       Date:  1986-03       Impact factor: 4.092

4.  Characteristics of aggregated immunoglobulin G as an immunologic phagocytic stimulus for granule enzyme release from human neutrophils.

Authors:  R J Smith; S C Speziale; R G Ulrich; B J Bowman
Journal:  Inflammation       Date:  1986-06       Impact factor: 4.092

5.  Human neutrophil phosphodiesterase. Calmodulin insensitivity and other properties.

Authors:  J E Smolen; S J Geosits
Journal:  Inflammation       Date:  1984-06       Impact factor: 4.092

6.  Early changes in cyclic AMP and calcium efflux during phagocytosis by neutrophils from normals and patients with chronic granulomatous disease.

Authors:  T Herlin; N Borregaard
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

7.  Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase.

Authors:  R M Clancy; J Leszczynska-Piziak; S B Abramson
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

8.  Phosphorylation of partially purified 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase from rat spleen.

Authors:  J Gomez-Cambronero; J M Mato; F Vivanco; M Sanchez-Crespo
Journal:  Biochem J       Date:  1987-08-01       Impact factor: 3.857

Review 9.  Activation of the respiratory burst oxidase in neutrophils: on the role of membrane-derived second messengers, Ca++, and protein kinase C.

Authors:  J D Lambeth
Journal:  J Bioenerg Biomembr       Date:  1988-12       Impact factor: 2.945

10.  An inhibitor of cyclic AMP-dependent protein kinase enhances the superoxide production of human neutrophils stimulated by N-formyl-methionyl-leucyl-phenylalanine.

Authors:  T Mitsuyama; K Takeshige; T Furuno; T Tanaka; K Hidaka; M Abe; N Hara
Journal:  Mol Cell Biochem       Date:  1995-04-12       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.